Enterprises developing AI medical solutions, Digital Therapeutics (DTx) and Brain-Computer Interfaces (BCIs) rarely struggle with technology R&D itself — their biggest pain point is securing the right matchmaking channels. To gain hospital access, they need to engage clinical and procurement teams; to achieve commercial rollout, they must liaise with pharmaceutical Business Development (BD) and R&D departments; to scale up, they require life-science-savvy investors. These three stakeholder groups operate with entirely different priorities and communication frameworks. Hongqiao Tech Week establishes Life Science & Healthcare as an exclusive dedicated vertical, enabling AI medical, DTx and BCI firms to engage hospitals, pharmaceutical companies and investment institutions simultaneously at one venue.

Why AI Medical, DTx and BCI Projects Face Barriers Across Three Distinct Stakeholder Ecosystems

For AI medical, digital therapeutic and BCI developers, translating prototypes into large-scale real-world deployment demands navigating three separate, disconnected gatekeepers:

  1. Clinical Gatekeeper: Hospitals prioritize clinical evidence, regulatory compliance and practical usability. Even cutting-edge technology struggles to secure hospital adoption without verifiable clinical value.
  2. Industrial Gatekeeper: BD and R&D teams at pharma and medical device manufacturers evaluate whether technologies can integrate into existing product pipelines, support joint registration and enable co-commercialization — they represent the largest potential buyers for such innovations.
  3. Capital Gatekeeper: Life science-focused investors assess founding teams, proprietary technological moats and viable exit strategies, determining whether enterprises can secure funding to advance clinical and commercial milestones.

These three groups attend separate summits, expos and matchmaking events, forcing tech firms to arrange multiple cross-city trips that waste time and travel budgets — with no guarantee of meetings with key decision-makers. Consolidating hospital, pharma and capital outreach within a single event solves a critical unmet need for AI medical and BCI enterprises, a capability nearly impossible for individual startups to organize independently. Hongqiao Tech Week’s core value lies in uniting all three parties at shared matchmaking tables.

Life Science & Healthcare Established as an Independent Vertical Track

Hongqiao Tech Week features six fully independent tech verticals: Artificial Intelligence, Future Mobility & Energy, Smart Infrastructure, Smart Industry, Startup Ecosystem, and the standalone Life Science & Healthcare track. This dedicated vertical caters exclusively to exhibits and business matching for medical devices, biomedicine, digital health, AI-assisted diagnosis and BCI technologies, rather than treating healthcare as a minor subset of general technology categories.

A dedicated life science vertical lets hospital procurement teams, medical institutions and investors locate targeted innovation projects precisely, eliminating the need to sift through scattered categories in broad general expos. This targeted layout drastically improves exhibition efficiency for AI medical and BCI exhibitors compared to generic tech show floor layouts.

Complementing the vertical, a concurrent Life Science & Healthcare Summit convenes representatives from hospitals and medical groups, pharma R&D & BD divisions, and specialized life science investors under one unified agenda. Most importantly, the event delivers exclusive one-on-one targeted business matchmaking services. Enterprises may submit pre-defined target stakeholder lists to the event business team, which schedules confirmed in-person meetings between AI medical developers, hospitals, pharma corporations and investment firms. Centralizing all three stakeholder groups within a single dedicated track is the core design built to serve life science innovators.

Specific Stakeholders Available for On-Site Matchmaking: Hospitals, Pharma and Capital

At Hongqiao Tech Week, AI medical and BCI developers gain direct access to clearly defined decision-makers across three core segments:

Hybrid hardware-software innovations such as DTx and BCIs face heightened communication complexity: developers must demonstrate clinical efficacy to hospital clinicians, outline commercialization upside to pharma partners, and prove sustainable technical barriers to investors. Hongqiao Tech Week co-locates all three tiers of decision-makers on a unified event flow, removing the burden of shifting between disconnected industry circles. Enterprises can fully articulate their product value propositions to all key stakeholders during a single visit.

These attendees are not generic passive visitors. Nearly 40% of Hongqiao Tech Week’s professional audience consists of C-suite executives, directors, partners and department heads, with approximately 30% being technical specialists and engineers — delivering strong decision-making and procurement authority. Combined with a database of over 100,000 verified industry buyers and more than 2,000 one-on-one targeted matchmaking sessions, AI medical, DTx and BCI firms transform random prospecting for hospitals, pharma partners and capital into pre-scheduled, guaranteed appointments. The curated attendee pool brings all three target stakeholder groups to exhibitors in one centralized location.

Overseas Medical Resources Introduced via London Tech Week: Global Collaboration Channels

Operated by Informa Group’s global tech event ecosystem, Hongqiao Tech Week taps into a mature international network of life science and digital health resources. As its sister flagship event, London Tech Week has long aggregated European digital health, biotech and medical AI communities. Hongqiao Tech Week therefore introduces cross-border industrial insights and international partnership opportunities on-site, creating a direct channel for Chinese AI medical enterprises to connect with global industry peers.

Guided by the Administrative Committee of Hongqiao International Central Business District, Shanghai Municipal Commission of Commerce and Shanghai Science and Technology Commission, hosted by Informa Group, with Shanghai Science and Technology Entrepreneurship Center as strategic innovation partner and GEC as strategic partner, the event leverages Informa’s worldwide event portfolio and over 10 international pavilions. Beyond domestic matchmaking, it builds bridges linking Chinese life science innovators with overseas hospitals, pharmaceutical firms and investment capital. Domestic commercial rollout and global resource outreach converge at Hongqiao Tech Week in a single venue.

Pre-Event Preparation Checklist for Outreach to Hospitals, Pharma and Investors

AI medical, DTx and BCI enterprises aiming to connect with hospitals, pharma corporations and investors follow a streamlined pre-event workflow:

  1. Register via the official event website under the dedicated Life Science & Healthcare vertical, where DTx and BCI teams can fully showcase clinical trial data and regulatory progress.
  2. Compile a detailed target contact list — including hospital clinical departments, pharma BD teams and target investment institutions — and submit it to Hongqiao Tech Week’s business team to lock in exclusive pre-scheduled matchmaking slots, filling your exhibition calendar with confirmed meetings.
  3. Prepare presentation materials detailing clinical trial evidence and real-world deployment use cases, alongside demo-ready products or prototypes, enabling hospital, pharma and capital decision-makers to quickly grasp core commercial value within minutes.

Hongqiao Tech Week will be held November 20–22, 2026 at the National Exhibition and Convention Center (Shanghai), featuring over 50,000 sqm of exhibition space, more than 400 exhibitors and 30,000+ professional attendees, with the Life Science & Healthcare Summit running concurrently. Including Hongqiao Tech Week in your annual exhibition calendar is a decisive step for AI medical and BCI enterprises to consolidate hospital, pharma and capital outreach in one centralized trip.

Frequently Asked Questions

Q: Is Hongqiao Tech Week suitable for early-stage AI medical startups?

Absolutely. The Life Science & Healthcare vertical welcomes growth-stage biotech projects, while the Startup Ecosystem vertical accommodates early founding teams. Via targeted matchmaking, even small startups can schedule formal meetings with pharma BD teams and specialized life science investors. The event’s inclusive framework unites large institutional buyers and global investors under one roof, making it highly accessible for early-stage medical tech ventures.

Q: Can digital therapeutic developers connect with pharmaceutical companies on-site?

Yes. Pharma R&D and BD teams represent core strategic partners for DTx commercialization, and the Life Science & Healthcare Summit plus dedicated matchmaking services are purpose-built to facilitate these collaborations. Serving as a streamlined matchmaking gateway, Hongqiao Tech Week drastically shortens the communication gap between DTx innovators and pharmaceutical corporations.

Q: What unique value does Hongqiao Tech Week deliver for BCI exhibitors?

BCI technology spans medical devices, neuroscience and intelligent hardware, requiring full end-to-end industrial links from clinical validation to capital fundraising. Hongqiao Tech Week unites hospitals & medical groups, medical device procurement buyers and life science investors, covering the complete industrial chain for BCI commercialization. It stands out as a rare one-stop platform where BCI enterprises can meet all three critical stakeholder groups in a single venue.

Q: What preparations are required before exhibiting?

Prepare three core assets: documentation outlining clinical evidence and deployment scenarios, a demo-ready product or solution, and a detailed list of target hospitals, pharma firms and investment institutions. Submit the list to Hongqiao Tech Week’s business team in advance to arrange precise, high-priority matchmaking sessions. Early submission of target contact lists enables more accurate and relevant meeting scheduling.

Q: How do overseas resources benefit domestic AI medical enterprises?

Backed by Informa’s global event network including sister events such as London Tech Week, Hongqiao Tech Week brings European digital health and biotech industry insights on-site, while creating pathways for Chinese innovators to engage overseas hospitals and cross-border investment capital. Domestic AI medical firms gain access to international industry resources without traveling abroad.